Ilsung Pharm Asset Resilience Ratio
Ilsung Pharm asset resilience ratio. Ilsung Pharm (003120) has an Asset Resilience Ratio of 26.89% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Ilsung Pharm (003120) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ilsung Pharm (2013–2025)
Asset resilience ratio of Ilsung Pharm from 2013 to 2025. This chart shows how Ilsung Pharm's Asset Resilience Ratio has changed over time. Read 003120 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ilsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ilsung Pharm total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩105.97 Billion | 26.89% |
| Total Liquid Assets | ₩105.97 Billion | 26.89% |
Asset Resilience Insights
- Very High Liquidity: Ilsung Pharm maintains exceptional liquid asset reserves at 26.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ilsung Pharm Industry Peers by Asset Resilience Ratio
Compare Ilsung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Ilsung Pharm Asset Resilience Ratio by Year (2013–2025)
Ilsung Pharm asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Ilsung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.21% | ₩105.65 Billion ≈ $71.60 Million |
₩403.01 Billion ≈ $273.11 Million |
-2.02pp |
| 2024-12-31 | 28.23% | ₩112.05 Billion ≈ $75.93 Million |
₩396.88 Billion ≈ $268.96 Million |
+10.26pp |
| 2023-12-31 | 17.97% | ₩75.33 Billion ≈ $51.05 Million |
₩419.19 Billion ≈ $284.08 Million |
+12.51pp |
| 2022-12-31 | 5.46% | ₩27.01 Billion ≈ $18.30 Million |
₩494.42 Billion ≈ $335.06 Million |
+1.90pp |
| 2021-12-31 | 3.57% | ₩13.24 Billion ≈ $8.97 Million |
₩371.38 Billion ≈ $251.68 Million |
+1.13pp |
| 2020-12-31 | 2.43% | ₩9.03 Billion ≈ $6.12 Million |
₩371.22 Billion ≈ $251.57 Million |
-1.54pp |
| 2019-12-31 | 3.98% | ₩14.69 Billion ≈ $9.95 Million |
₩369.52 Billion ≈ $250.42 Million |
-11.15pp |
| 2018-12-31 | 15.13% | ₩52.52 Billion ≈ $35.59 Million |
₩347.26 Billion ≈ $235.34 Million |
+11.89pp |
| 2017-12-31 | 3.24% | ₩11.25 Billion ≈ $7.62 Million |
₩347.46 Billion ≈ $235.47 Million |
-0.87pp |
| 2016-12-31 | 4.10% | ₩13.89 Billion ≈ $9.41 Million |
₩338.50 Billion ≈ $229.40 Million |
-13.18pp |
| 2015-12-31 | 17.28% | ₩63.43 Billion ≈ $42.99 Million |
₩367.03 Billion ≈ $248.73 Million |
-7.46pp |
| 2014-12-31 | 24.74% | ₩93.61 Billion ≈ $63.44 Million |
₩378.37 Billion ≈ $256.42 Million |
+1.20pp |
| 2013-12-31 | 23.54% | ₩87.73 Billion ≈ $59.45 Million |
₩372.66 Billion ≈ $252.55 Million |
-- |
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more